Trials / Terminated
TerminatedNCT04826484
Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel
A Randomized Trial Evaluating Use of Long-Acting Liposomal Bupivacaine (Exparel®) in Reducing Narcotic Pain Requirements in Pediatric Patients Undergoing Minor Urologic Procedures
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Johns Hopkins University · Academic / Other
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the utility of long-acting liposomal bupivacaine (Exparel®) in improving pain scores and reducing narcotic pain requirements in pediatric patients following minor urologic procedures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Exparel 133 miligrams per 10 milliliter injection | Local wound infiltration with Exparel 133 miligrams per 10 milliliter injection |
| DRUG | Bupivacaine Hydrochloride | Local wound infiltration with 0.25% bupivacaine. |
Timeline
- Start date
- 2021-10-01
- Primary completion
- 2023-04-26
- Completion
- 2023-04-26
- First posted
- 2021-04-01
- Last updated
- 2023-12-26
- Results posted
- 2023-12-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04826484. Inclusion in this directory is not an endorsement.